Specifications
- Purity
- ≥95% (HPLC)
- Appearance
- White crystals
- Identity
- 1H-NMR
Properties
- Solvents
- DMSO (25 mg/ml), chloroform
Category: API's & Intermediates
Non-hydroxamate HDAC inhibitor (HDACi) (IC50: 32, 48 and 41nM for HDAC4, HDAC1 and HDAC6, respectively). Cell-permeable prodrug that is intracellularly converted to a potent HDAC inhibitor. Predicted to exhibit a similar HDAC binding mode as that of SAHA, interacting with the active-site zinc targeting group. Shown to exhibit comparable antiproliferative and apoptotic activity as SAHA against various cancer cell lines. Inhibits growth of various cancer cells in vitro (EC50 = 1.1 – 9.1mM). Also reactivates latent HIV-1 gene expression.
Synonyms | NCH 51, Cpd 51, S-[6-(4-Phenyl-2-thiazolylcarbamoyl)hexyl] thioisobutyrate |
---|---|
Purity | ≥95% (HPLC) |
Appearance | White crystals |
CAS-Number | 848354-66-5 |
Molecular Formula | C20H26N2O2S2 |
Molecular Weight | 390.56 |
Identity | 1H-NMR |
Solvents | DMSO (25 mg/ml), chloroform |
Smiles | CC(C)C(SCCCCCCC(NC1=NC(C2=CC=CC=C2)=CS1)=O)=O |
InChi Key | MDYDGUOQFUQOGE-UHFFFAOYSA-N |
Shipping | AMBIENT |
Short Term Storage | +4°C |
Long Term Storage | +4°C |
Handling Advice | Protect from light and moisture. |
Use / Stability | Stable for at least 2 years after receipt when stored at +4°C. |
Hazard statements | H318-H413 |
Precautionary statements | P280-P305 + P351 + P338 |
GHS Symbol | GHS05 |
Signal word | Danger |
Transportation | Not dangerous goods |
References | (1) T. Suzuki, et al., J. Med. Chem. 48, 1019 (2005), (2) T. Sanda, et al., Leukemia 21, 2344 (2007), (3) T. Suzuki, et al.,Bioorg. Med. Chem. Lett. 17, 1558 (2007), (4) A.F. Victoriano, et al., FEBS Lett. 585, 1103 (2011) |
InChi | InChI=1S/C20H26N2O2S2/c1-15(2)19(24)25-13-9-4-3-8-12-18(23)22-20-21-17(14-26-20)16-10-6-5-7-11-16/h5-7,10-11,14-15H,3-4,8-9,12-13H2,1-2H3,(H,21,22,23) |
Quantity | 5 mg, 25 mg, Bulk |